EMA Withdrawn: Ketek (telithromycin) — Aventis Pharma S.A.

View source ↗

Summary

Telithromycin (Ketek) has been withdrawn from the European market by Aventis Pharma S.A. after regulatory assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis Chronic
• Community-acquired Infections
• Pharyngitis
• Pneumonia Bacterial
• Sinusitis
• Tonsillitis

Drugs mentioned

• Ketek (telithromycin)

Snippet

Status: Withdrawn. Therapeutic area: Sinusitis;Tonsillitis;Bronchitis, Chronic;Pharyngitis;Community-Acquired Infections;Pneumonia, Bacterial. MAH: Aventis Pharma S.A.. Decision date: 07/02/2017